The present invention is directed towards process for preparation of an optically pure (Sp)-Sofosbuvir of Formula-I and its intermediate namely (Sp)-isomer of isopropyl alanyl phosphoramidate of Formula (III) thereof.                        Formula-(I)                      Formula (III)

The present invention relates to an improved process for preparation of Vildagliptin intermediate, 1-chloro acetyl (S)-2-cyano pyrrolidine.

The present invention relates to a process for the preparation of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophen-carboxamide (I) by reacting 5-chlorothiphene-2-carbonyl chloride and 4-[4-((S)-4-aminomethyl-2-oxoimidazolidin-l-yl)phenyl]morpholine-3-one hydrochloride ...

Abstract The present invention relates to novel compounds useful as reference markers for the analysis of Deferasirox and pharmaceutical formulations thereof. The present invention deals with the new impurities of Deferasirox i.e. impurity E and impurity F  Process for preparing and isolating thereof  includes me...

The present invention relates to the novel process for the preparation of Ticagrelor intermediate.

The present invention relates to an improved process of preparation of Icatibant (Formula-I) using solid phase synthesis with reduced impurities, high yield and purity.

The present invention refers to new crystalline solvate form of Ibrutinib and its process for the preparation thereof.

The present invention provides Novel crystalline polymorphic form of DL-lactate salt of Panobinostat of Formula-I. This invention also provides process for preparation of crystalline forms of Panobinostat DL-lactate.

The invention encompasses methods of preparing beta crystalline form of Vortioxetine hydrobromide and a novel compound as reference marker of vortioxetine or its pharmaceutically acceptable salts.

The present invention relates solid forms of Osimeritnib Mesylate and the preparation thereof. The present invention also relates to an improved process of preparation of Osimeritinib Mesylate.

Abstract The present invention relates to an improved process for the preparation of vemurafenib of formula I formula I

The present invention relates to process for preparing formulations of Iloperidone. The iloperidone formulation of the present invention exhibits desired physico chemical properties.

Abstract The present invention relates to the novel process for the preparation of Vildagliptin. Further  the present invention relates to novel purification process for the Vildagliptin comprises acid base treatment to crude Vildagliptin.

The present invention is directed to processes for preparing Stable amorphous form of Sofosbuvir of Formula-I, to pharmaceutical compositions containing them, and to method of treatment using the same. Formula-I

The present invention relates to an improved process for the preparation of macitentan of formula I formula I

The present invention relates to a novel process for the preparation of Silodosin.

The present invention relates to novel polymorph of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl}-1 -methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester compound of formula I (dabigatran etexilate).

The present invention describes novel forms of Azilsartan mcdoxomil potassium (Formula I), process for their preparation and pharmaceutical compositions containing them. More particularly, the present invention revels new polymorph of Azilsartan medoxomil potassium process of preparing them and various pharmaceutica...

The present invention relates to an improved process for the preparation of pure Ethylmethylcarbamic acid 3-[(lS)-l-(dimethyIamino) ethyl] phenyl ester of formula (I) or commonly known as (S)- Rivastigmine base.

The present invention-1 relates to an improved reversed-phase liquid chromatographic (RP-LC) method for the quantitative determination of rivaroxaban and its known impurities. The present invention further provides a stability indicating analytical method using the samples generated from forced degradation studies. ...

The present invention relates to process for preparing tadalafil formulation. The present invention provides the simple and robust process for preparing the tadalafil formulation which exhibits the desired dissolution characteristics.

The present invention relates to an improved process for the preparation of Fesoterodine and pharmaceutically acceptable salts thereof. The present invention particularly relates to a process for the preparation of fesoterodine and pharmaceutically acceptable salts thereof which involves use and preparation of R...

The present invention relates to an improved process of preparation of Afatinib. The invention also relates to process of preparation of Subtantially Pure Form-A of Afatinib dimaleate.

Abstract The present invention relates to the process for the preparation of Irbesartan.

The present invention relates to stable pharmaceutical composition of fesoterodine or pharmaceutically acceptable salts or solvates thereof and the process for preparing the same. Further the present invention relates to stable pharmaceutical composition comprising fesoterodine a stabilizer and at least one release ...

The present invention relates to an improved indirect capillary electrophoresis methodology for the quantitative determination of pentosan polysulphate sodium by using internal standard . The present invention further provides a relative migration times and relative response of major secondary peaks (1-9) with respe...

The present invention relates to the technique in which the residual level of a– crystalline form in d- crystalline form and dd- crystalline form of Ivabradine hydrochloride drug substance or drug product of formula (I) identified by Solid State NMR. Formula (I)

The present invention relates to a process for the purification of Etoricoxib. More particularly present invention provides process for the preparation of highly pure Etoricoxib which is substantially free of 6-chloro-2-(6-methylpyridne-3-yl)-3-[4-(methylsulfonyl)phenyl]-l,8-naphthyridine of formula I. ...

The present invention relates to an improved gas chromatographic (GC) method for the determination of chromatographic purity and related impurities and isomeric impurities of 1-hexanol.

The present invention provides an improved process for preparation of teriflunomide of formula I.

The present invention relates to an improved process for obtaining high purity of Dronedarone HC1 formula (I).

The present invention relates to an improved process for preparing Losartan Potassium of formula (I).

This invention involves process for preparation of Lurasidone hydrochloride from Lurasidone base by using acetic acid as a solvent.

The present invention provides an improved process for the preparation of Axitinib of formula-I and its substantially pure Form-IV.

The present invention relates to the novel impurities of Bosutinib, preparation of impurities and characterization data thereof. also, an improved process for the preparation of Bosutinib and its polymorphic forms.

ABSTRACT The present invention relates to a stable pharmaceutical composition for sublingual and/or buccal administration comprising asenapine or pharmaceutically acceptable salt thereof, antioxidant. water-soluble polymer, water soluble diluent, disintegrant and optionally one or more pharmaceutically acceptable...

The present invention relates to an improved process for the preparation of of sulfamate esters, more specifically to the process for pure and stable Topiramate of formula (I).

The present invention provides a novel pure amorphous form of vilazodone hydrochloride, process for preparation, pharmaceutical compositions, and method of treating thereof.

The present invention relates to an improved process for the purification of (S)-(2- Chlorophenyl)-6,7-dihydrothieno[3,2-C]pyridine-5(4H)-acetic acid methyl ester compound of formula I (Clopidogrel bisulphate)

The present invention relates to a novel process for the preparation of substantially pure trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole (Asenapine) of formula (I). It also relates to novel salts of intermediates i.e. 5-nitro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]ox...

The present invention relates to a novel process for the preparation of crystal G of Febuxostat. The present invention particularly relates to a process for the preparation of crystal G of Febuxostat using a mixture of a ketone and water.

TITLE OF THE INVENTION: “Process for making crystalline alpha-form of ivabradine hydrochloride”. ABSTRACT The present invention relates to an improved process for the preparation of the pharmaceutically advantageous crystalline alpha-form of ivabradine hydrochloride.

The present invention relates to a solid oral preparation of febuxostat and to a process for preparation thereof. More particularly, it relates to a solid oral preparation of febuxostat which is stable and has desired pharmacokinetic properties.

STABLE PHARMACEUTICAL COMPOSITION COMPRISING TELMISARTAN AND AMLODIPINE BESYLATE ABSTRACT The invention relates to a single layer solid oral pharmaceutical composition comprising telmisartan or a pharmaceutically acceptable derivative thereof and at least one calcium channel blocker and process for preparation...

The present invention relates to an improved process for the preparation of 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-yl-carboxylicacid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide methanesulfonate salt (Dabigatran etexilate mesylate ). Further, the present invention provides...

"PHARMACEUTICAL COMPOSITION OF PRASUGREL" The present invention relates to a stabilized pharmaceutical composition comprising Prasugrel base in micronized form, a surfactant and / or a stabilizer which is bioequivalent to the EFIENT® (prasugrel hydrochloride marketed formulation). The present invention further rela...

Abstract The present invention relates to process for the preparation of Canagliflozin (I), chemically known as (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol useful as Sodium–glucose co-transporters (SGLTs) inhibitors. The present inven...

The present invention relates to novel crystalline form A, form B and Form C of Apixaban (I) and process for their preparation.

ABSTRACT The present invention relates to a novel synthetic route to N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl] -2-methyl-4-pyrimidyl] amino]-5-thiazolformamide of the formula I and also relates to the process for the preparation of novel amorphous forms of dasatinib (formula I). ...

The present invention provides an improved process for the preparation of Apremilast of formula-I using novel intermediates. The present invention also relates to the novel crystalline polymorphic form of Apremilast.

The present invention relates to an improved process of preparation of Ivacaftor. The invention also relates to novel polymorph forms of Ivacaftor.

Abstract The present invention relates to the novel process for the preparation of Ticagrelor intermediate.

The present invention relates to novel intermediates i.e. isopropanolate solvate of 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl] benzimidazol -5-yl-carboxylicacid -N- (2-pyridyl) -N- (2-ethoxy carbonyl ethyl) -amide hydrochloride of formula (VIIa) and crystalline form II of 1-methyl-2-[N-(4-amidinophenyl)-aminomethy...

The present invention relates to an improved process for the preparation of Lacosamide having formula (I).

The present invention relates to novel polymorph of riociguat and process for preparing the polymorph. The present invention also relates to the improved process for the preparation of riociguat.

ABSTRACT The present invention relates to a multiple packing and vacuum sealed pack comprising Ivabradine hydrochloride.

The present invention deals with a new method of obtaining chemically pure and pharmaceutically acceptable Dabigatran or its pharmaceutical acceptable salt having purity at least about 99 % , wherein the content of Dabigatran individual impurity is less than 0.03-0.15 % as measured by HPLC. The invention also disclo...

The present invention relates to an improved reversed-phase liquid chromatographic (RP-LC) method for the quantitative determination of ivabradine hydrochloride. The present invention further provides a stability indicating analytical method using the samples generated from forced degradation studies. ...

The present invention relates to an improved reversed-phase liquid chromatographic (RP-LC) method for the quantitative trace level determination of L-Serine content in D-Serine.

The present invention relates to an improved reversed-phase liquid chromatographic (RP-LC) method for the quantitative determination of Dabigatran etexilate mesylate. The present invention further provides a stability indicating analytical method using the samples generated from forced degradation studies. ...

The present invention relates to improved process for preparation of Ivabradine Adipate.

The present invention relates to an improved reversed-phase liquid chromatographic (RP-LC) method for the quantitative determination of fesoterodine fumarate. The present invention further provides a stability indicating analytical method using the samples generated from forced degradation studies. ...

The present invention relates to novel crystalline form A of Vardenafil base of formula (II) and the process for its preparation.

The present invention relates to an improved process for the preparation of Ticagrelor.

The present invention relates to an improved process for the preparation of pure crystalline for I of Agomelatine

The present invention relates pharmaceutical composition comprising stable amorphous form of Agomelatine for oral administration having improved in dissolution profile and process for preparing stable amorphous form of agomelatine which is stable under accelerated condition.

Abstract The present invention relates to a novel process for the preparation of trans-5-chloro-2-methyl-2 3 3a 12b-tetrahydro-1H-dibenz[2 3:6 7]oxepino[4 5-c]pyrrole (Asenapine) of formula (I). It also relates to novel intermediates i.e. 2-[(E)-2-(2-bromophenyl)ethenyl]-4-nitrophenyl acetate of formula (V)  2-[(...

The present invention relates to an improved reversed-phase liquid chromatographic (RP-LC) method for the quantitative determination of Prasugrel HC1. The present invention further provides a stability indicating analytical method using the samples generated from forced degradation studies.

The present invention relates to an improved reversed-phase liquid chromatographic (RP-LC) method for the quantitative determination of febuxostat. The present invention further provides a stability indicating analytical method using the samples generated from forced degradation studies.

The present invention relates to an improved reversed-phase liquid chromatographic (RP-LC) method for the quantitative determination of fingolimod hydrochloride. The present invention further provides a stability indicating analytical method using the samples generated from forced degradation studies. ...

The present invention relates to an improved reversed-phase liquid chromatographic (RP-LC) method for the quantitative determination of Dabigatran etexilate mesylate. The present invention further provides a stability indicating analytical method using the samples generated from forced degradation studies. ...

The present invention relates to an improved reversed-phase liquid chromatographic (RP-LC) method for the quantitative determination of asenapine maleate and its known impurities. The present invention further provides a stability indicating analytical method using the samples generated from forced degradation studi...

The present invention relates to an improved process fc"f the preparation of Minodronic acid. The present invention particularly relates to a process for the preparation of Minodronic acid from imidazo [l,2-a]pyridine.

The present invention provides improved process for the preparation of 4-substitude 1, 4-dihydropyrine, more particularly to the preparation of nisoldipine formula (I) with efficient parameters such as improvement in yield and purity Formula (I)

The present invention relates Linezolid premix and process for the preparation of the said premix. The present invention also relates to pharmaceutical compositions comprising said Linezolid premix.

The present invention relates to stable microcrystalline form of Linezolid, which is stable to micronization, and processes for preparation thereof. Further the present invention also relates to a multiple packing and vacuum sealed pack comprising Linezolid, or stable microcrystalline form of Linezolid and optionall...

Abstract The present invention relates to Ivabradine hydrochloride premix comprising Ivabradine and process for preparing said premix. The present invention also relates to pharmaceutical compositions comprising said Ivabradine hydrochloride premix.

The present invention relates to an improved process for the preparation of Fesoterodine and pharmaceutically acceptable salts thereof. The present invention particularly relates to a process for the preparation of Fesoterodine from O-benzyl tolterodine.

Abstract The present invention relates to an improved process for the preparation of Tolterodine and pharmaceutically acceptable salts thereof. The present invention particularly relates to a process for the preparation of Tolterodine and pharmaceutically acceptable salts thereof which involves use and preparat...

Abstract The present invention relates to an improved process for the preparation of vilazodone and its pharmaceutically acceptable salts thereof.

Abstract The present invention relates to the new impurities of Fesoterodine  Fesoterodine symmetric dimer impurity and asymmetric dimer impurity process for preparing and isolating thereof. The invention also deals with analytical standards and analytical methods used for the control of the production process and ...

Abstract The present invention relates to an improved and industrially advantageous process for the preparation of Ailsartan medoxomil of formula (I) in high yield and purity. Formula I

Abstract The present invention describes novel crystalline form AL of Azilsartan medoxomil potassium  process for their preparation and pharmaceutical compositions containing them.

The present invention relates to an improved reversed-phase liquid chromatographic (RP-LC) method for the quantitative determination of linezolid. The present invention further provides a stability indicating analytical method using the samples generated from forced degradation studies.

The present invention relates to a novel process for the preparation of Silodosin.

The present invention encompasses an improved process for the preparation of 2-chloro acrolene which is used in the syntesis of Etoricoxib of formula (I). More particularly present invention provides process for the preparation of Etoricoxib which gives Etoricoxib in high yield and purity. Formula (I) ...

The present invention relates to an improved indirect capillary electrophoresis methodology for the quantitative determination of Phosphate and Phosphite in Bisphosphonates. The present invention further provides migration times of Phosphate and Phosphite peaks.

The present invention provides novel process for the preparation crystalline sorafenib tosylate of formula (I). Formula I

The present invention relates to an improved process for the preparation of crystalline form 1 of Fingolimod Hydrochloride.

The present invention relates to a novel process for the synthesis of Gefitinib.

The present invention relates to the Process for the preparation of Apixaban and novel intermediates useful in the synthesis of Apixaban (I)

Abstract The present invention encompasses a process for the preparation of highly pure 2-[(6-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]benzonitrile (II) which is used in the synthesis of Alogliptin benzoate of formula (I). More particularly present invention provides process for the preparation of Alog...

The present invention provides polymorphic forms of Vortioxetine of and its pharmaceutically acceptable salts. Specifically the present invention relates to the novel crystalline forms of Vortioxetine or its pharmaceutically acceptable salts. Moreover, the present invention also provides an amorphous form of Vortio...

The present invention relates solid forms of Osimeritnib Mesylate and the preparation thereof. The present invention also relates to an improved process of preparation of Osimeritinib Mesylate.

The present invention provides a novel crystalline form Al-1 of Daclatasvir dihydrochloride of Formula-1 and its preparation thereof.

The present invention provides a novel crystalline polymorphic form of Lumacaftor of Formula (1) and its preparation thereof.

The present invention provides solid state forms of Venetoclax, particularly relates to novel alkali metal salt and/or DMF solvate form of Venetoclax or its salt. The present invention also relates to process for the preparation Venetoclax by using the said solid state form of Venetoclax. Dated this 02nd January ...

PHARMACEUTICAL COMPOSITION OF OSIMERTINIB ABSTRACT: The present invention relates to pharmaceutical composition comprising osimertinib or a pharmaceutically acceptable salt thereof and at least one diluent. The process to prepare such a pharmaceutical composition is also disclosed.

Title: An improved process of preparation of Ivosidenib The present invention relates to an improved process of preparation of Ivosidenib a compound of Formula (I) and pharmaceutical compositions comprising the same.

Title: Novel Solid Forms of Filgotinib and its pharmaceutically acceptable salts and preparation thereof. The present invention relates to solid forms of Filgotinib base as well as Filgotinib maleate and the preparation method thereof. Further, the present invention provides solid premix of Filgotinib maleate with ...

The present invention relates to extended release potassium citrate tablet containing carnauba wax, prepared by roller compaction process, which does not involve melting or heating of carnauba wax. The extended release potassium citrate tablet of present invention has superior dissolution, friability and improved pr...

The invention relates to an improved process for the preparation of amorphous form of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole compound of formula I (asenapine maleate)

The present invention relates to novel crystalline form AL of erythromycin ethyl succinate and its process for preparation.

The present invention relates to process for preparation of Brexpiprazole of formula-I and intermediates thereof. The present invention is further directed to process for the preparation of anhydrous form of Brexpiprazole, pharmaceutical compositions containing them.           Formula-I

The present invention is directed towards a process for preparing stable amorphous form of Ledipasvir of Formula-I, its pharmaceutical compositions and method of treatment using the same.

The present invention relates to a pharmaceutical composition of an canagliflozin and one or more pharmaceutical excipients, wherein the composition is free of binder. The present invention also relates to a method of preparing the pharmaceutical composition of canagliflozin by dry granulation or direct compression....

The present invention is directed towards the process for preparing Etoricoxib of Formula-I.                   Formula-I

The present invention is directed to process for preparation of Olaparib of formula-I. The present invention further relates to novel polymorphic forms of Olaparib, pharmaceutical compositions containing them, and method of treatment using the same.           Formula-I

Abstract Title: Novel polymorphic forms of Lenvatinib mesylate and preparation process of Lenvatinib The present invention provides a novel crystalline solvate of mesylate of Lenvatinib represented by formula-1 and improved process for preparation of Lenvatinib.

The present invention relates to an improved process for preparation of sincalide. The invention also relates to an improved process for preparation of sincalide by combining solid phase and liquid phase method.

TITLE: NOVEL ANHYDROUS CRYSTALLINE FORM A OF CANAGLIFLOZIN AND PROCESS FOR PREPARATION THERE OF ABSTRACT The present invention relates to novel anhydrous crystalline form A of Canagliflozin (formula-1), process for preparation and pharmaceutical compositions thereof.             Formula-I ...

TITLE OF THE INVENTION: “PROCESS FOR THE PREPARATION OF LEDIPASVIR AND POLYMORPHS THEREOF” Abstract The present invention is directed towards process for preparing Ledipasvir of Formula-I. The present invention further relates to novel polymorphic forms of Ledipasvir, pharmaceutical compositions containing them,...

An improved process for preparation of Obeticholic Acid The invention relates to an improved process for the preparation of compound of formula (A), which is an intermediate in the preparation of Obeticholic acid or its analogous compounds thereof. COOR 1 PG2O O CH3 H H H H CH3 H3C H R Formula (A) ...

Title: An improved process for preparation of Palbociclib Abstract The invention relates to an improved process of preparation of Palbociclib of Formula-(I) and its intermediate thereof.

TITLE: RECYCLING PROCESS FOR PREPARING TENOFOVIR ALAFENAMIDE DIASTEREOMERS AND SALTS THEREOF ABSTRACT The present invention relates to a recycling process for preparation of (R,S,S)-Tenofovir Alafenamide from (R,R,S)-Tenofovir Alafenamide.

The present invention relates to an improved process for purification of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate compound of formula I (asenapine maleate) which is free from process related impurities.

The present invention relates to a solid oral pharmaceutical composition comprising Apixaban particles having a D90 more than 89 µm, and a pharmaceutically acceptable carrier, is bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.

The present invention relates to a tablet of Brexpiprazole or salt of thereof and method of preparing the same comprising particles of brexpiprazole having particle size (D90) less than about 70 microns and tablet formulated using hydrophilic lubricant and it is devoid of Binder.

TITLE: NOVEL POLYMORPHIC FORM OF IBRUTINIB: SUCCINIC ACID CO-CRYSTAL ABSTRACT The present invention relates novel polymorph of co-crystals of Ibrutinib, Bruton"s tyrosine kinase (Btk) inhibitor, with succinic acid. More particularly relates to solvated form of co-crystal of Ibrutinib with succinic acid of form...

TITLE OF THE INVENTION: “SOLID STATE FORMS OF SACUBITRIL SALTS AND PROCESS FOR THE PREPARATION THEREOF” Abstract The present invention is directed to solid state forms of salts of Sacubitril of formula-I and process for the preparation thereof.           Formula-I               Dated this 26th Novembe...

The invention relates to an improved process of preparation of Lenalidomide of formula-(I). More specifically the invention relates to an improved process to obtain crystalline lenalidomide of Formula (I).

The present invention relates to the novel process for the preparation of Venetoclax.

Abstract Title: An improved process for preparation of Rucaparib Camsylate Present invention relates to improved process of preparation of compound of Formula-10 and optionally converts it to Rucaparib Camsylate. The present invention is also related to a novel intermediate(s) of Rucaparib Camsylate and its use i...

The present invention relates to stable pharmaceutical composition comprising sumatriptan or a pharmaceutically acceptable salts thereof in the form of ready to use injection, wherein the composition is substantially free of impurities detected at RRT 2.33 and 0.78, when measured by HPLC. Further, the invention p...

The present invention relates to an improved process for the preparation of Tipiracil. More, particularly the present invention relates to improved process for the preparation of Tipiracil in pure form and Crystal II of Tipiracil HCl.

TITLE OF THE INVENTION: NOVEL INTERMEDIATES AND THEIR USE IN PREPARATION OF CLOFARABINE ABSTRACT The present invention relates to the novel intermediates and their use in preparation of Clofarabine of formula (I). Dated this 18th day of Feb. 2019 Dr. S. Ganesan ...

The present invention is directed to process for characterization of Glatiramer acetate. The present invention further relates to process for characterization of Glatiramer acetate using size exclusion chromatography coupled with ultra performance liquid chromatography (SEC-UPLC) and high resolution mass spectrometr...

The present invention relates to process for preparation of Form II and Form III of Elvitegravir of formula-I. The present invention further relates to pharmaceutical compositions containing them, and method of treatment using the same.

TITLE OF THE INVENTION: “PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM I OF SELEXIPAG” ABSTRACT The present invention relates to process for the preparation of crystalline form I of Selexipag of compound of formula I. The present invention further relates to pharmaceutical compositions containing them, and met...

PHARMACEUTICAL COMPOSITION OF VORTIOXETINE HYDROBROMIDE The present invention relates to a stable pharmaceutical composition comprising Vortioxetine Hydrobromide which is stable during the prolonged duration. The present invention also discloses the method for the preparation of a pharmaceutical composition com...

Title: A novel polymorphic form of Brigatinib and process thereof Abstract The present invention relates to novel polymorphic form of Brigatinib and process of preparing thereof. Further, present invention involves novel acid addition salts of Brigatinib and process of preparing thereof. Present invention also pr...

Title: Process for the preparation of Cobimetinib ABSTRACT The present invention relates to novel process for the preparation of Cobimetinib. More particularly the present invention relates to the process for the preparation of Cobimetinib intermediate of Formula (IX) and Formula (VIII).      Dated this 1...

The present subject matter relates to a lyophilized composition comprising cyclophosphamide monohydrate used for injection. The subject matter further relates to a process for preparing such lyophilized cyclophosphamide monohydrate composition.

ABSTRACT IMPROVED PROCESS FOR THE PREPARATION OF TETRABENAZINE AND d6-TETRABENAZINE The present invention relates to improved process for the preparation of Tetrabenazine and d6-Tetrabenazine. Dated this 13th May 2019 Dr. S. Ganesan

TITLE OF THE INVENTION: “ACID ADDITION SALTS OF VELPATASVIR, ITS PREPARATION AND USE THEREOF” ABSTRACT The present invention provides acid addition salt of Velpatasvir, its preparation and use in the preparation of Velpatasvir of Formula (I). Formula (I) Dated this 23rd day of Sep. 2019 ...

Improved Process of Preparation of Venlafaxine The present invention discloses an improved process of preparation of venlafaxine of formula (I) using a micro-reactor, for obtaining the venlafaxine with high purity and reduced reaction time.

Title: Novel Solid Forms of Siponimod and its Process of Preparation thereof. The present invention relates to solid forms of Siponimod or its hemifumarate and its process of preparation thereof.

Title: Solid Forms of Siponimod and its process of preparation thereof The present invention relates to solid forms of Siponimod and its process of preparation thereof. Specifically relates to Amorphous form of Siponimod and Solid Dispersion of Siponimod.

ABSTRACT PROCESS FOR THE PREPARATION OF CARFILZOMIB AND ITS INTERMEDIATE The present invention relates to a process for the preparation of amino keto-epoxide, particularly (2S)-2-amino-4-methyl-1-[(2R)-2-methyl-2-oxiranyl]-1-pentanone of Formula (II) or its salt and use of compound of formula (II) obtained by the ...

Title: Process of preparation of benzimidazole compounds The application provides process of preparation of benzimidazole compounds such as Binimetinib and Selumetinib. Specifically, the present application provides intermediates for process of preparation of Binimetinib and Selumetinib.

Title: Novel process of preparation of Ivosidenib The present invention relates to novel process of preparation of Ivosidenib and pharmaceutical compositions comprising the same. Further, present invention also provides novel intermediates for process of preparation of Ivosidenib.

Title: An improved process for preparation of 5-substituted tetrazoles compounds. The present invention relates to an improved process for the preparation of pharmaceutically important 5-substituted tetrazoles compounds.

Abstract Title: An improved process for preparation of Betrixaban Maleate. The present application provides an improved process for preparation of Betrixaban Maleate.

Title: Process for the preparation of an amorphous form of Glasdegib Maleate. The present application provides a process of preparation of amorphous form of Glasdegib Maleate. The Present invention also relates to process of preparation of compound of Formula (II) and converting it to Glasdegib Maleate. Formul...

The present invention relates to a method for the quantitative determination of nitrosamine impurities in Angiotensin II Receptor Blockers (ARBs) such as valsartan, losartan, irbesartan, candesartan, olmesartan, and telmisartan or its salt or its ester using gas chromatography/mass spectroscopy (GC/MS). ...

Abstract Title: Novel Polymorph of Acalabrutinib and process of preparation thereof The present invention relates to polymorphic forms of Acalabrutinib and the preparation method thereof. Formula I

Title: An improved process of preparation of Ivosidenib The present invention relates to an improved process of preparation of Ivosidenib a compound of Formula (I) and pharmaceutical compositions comprising the same.

ABSTRACT: The present invention relates to stable injectable pharmaceutical composition comprising a therapeutically effective amount of epinephrine or its pharmaceutically acceptable salt thereof, a non-sulfite antioxidant and a chelating agent, wherein the pH of the composition is 2.2 to 5.0. Further, the inventi...

Abstract Title: An improved Process of preparation of Binimetinib The present application describes an improved process of preparation of benzimidazole compounds such as Binimetinib.

The present invention provides solid state forms of Venetoclax, particularly relates to novel alkali metal salt and/or DMF solvate form of Venetoclax or its salt. The present invention also relates to process for the preparation Venetoclax by using the said solid state form of Venetoclax.

TITLE: AN IMPROVED PROCESS FOR THE PREPARATION OF LASMIDITAN The present invention relates to an improved process for the preparation of Lasmiditan of Formula (I) and its pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of Lasmiditan intermediates. ...

ABSTRACT Pharmaceutical Composition of Ruxolitinib The present disclosure is directed to oral sustained release pharmaceutical compositions of ruxolitinib or a pharmaceutically acceptable salt thereof and process for preparation of such compositions.

ABSTRACT TITLE: AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB MALATE The present invention relates to a process for the preparation of Cabozantinib and salts thereof. The present invention also relates to a process for the preparation of Cabozantinib intermediates. ...

TITLE: AN IMPROVED PROCESS FOR THE PREPARATION OF PRUCALOPRIDE SUCCINATE. The present invention relates to an improved process for the preparation of Formula (I) and salts thereof. Dated this: Feb. 24th, 2023 Dr. S....

TITLE OF THE INVENTION –: PROCESS FOR PREPARING CRYSTALLINE FORM A OF TENOFOVIR ALAFENAMIDE HEMIFUMARATE ABSTRACT The present invention is directed to a novel process for preparation of crystalline form A of Tenofovir alafenamide hemifumarate of formula-I, pharmaceutical composition containing them, and method...

TITLE OF THE INVENTION: “PROCESS FOR THE PREPARATION OF FORM I AND FORM III OF SELEXIPAG” Abstract The present invention relates to process for the preparation of crystalline form I and form III of Selexipag of compound of formula I. The present invention further relates to pharmaceutical compositions containing...

The present invention relates to a solid oral preparations comprising alogliptin and metformin fixed dose combination and to a process for preparation thereof. More particularly it relates to a solid oral preparation of alogliptin and metformin fixed dose combination formulation which is stable and easy to manufactu...

The present subject matter relates to a solid oral pharmaceutical composition comprising ponatinib or a pharmaceutically acceptable salt thereof and at least one pharmaceutical acceptable excipient. The present subject matter also relates to pharmaceutical compositions comprising a solid dispersion of ponatinib or a...

Title – An improved process of preparation of Liraglutide. The present invention relates to an improved preparation process of Liraglutide.

PHARMACEUTICAL COMPOSITION OF LASMIDITAN AND PROCESS OF PREPARATION THEREOF ABSTRACT: The present subject matter relates to a solid oral pharmaceutical composition comprising lasmiditan or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the solid oral phar...

ABSTRACT: A pharmaceutically acceptable composition comprising an effective amount of a dasatinib or a pharmaceutically acceptable salt thereof, and a binder, one or more diluent or mixture thereof, a disintegrant, a lubricant, wherein said composition is devoid of dasatinib hydrate or solvate or any crystalline p...

TITLE OF THE INVENTION: “CONTINUOUS PROCESS FOR PREPARATION OF PREGABALIN” ABSTRACT The present invention relates to a continuous process for the preparation of Pregabalin of formula (I), reaction is carried out in an Oscillating Baffled Reactor. Dated this 02nd Aug, 2022 ...

Title: An improved process of preparation of Darolutamide The present invention relates to an improved process of preparation of Formula (I) and its intermediate thereof. I

Title: AN IMPROVED PROCESS FOR THE PREPARATION OF BEMPEDOIC ACID ABSTRACT The present invention relates to an improved process for the preparation of Bempedoic acid of formula (I). Formula (I) Dated this 21th April 2022 Dr. S.Ganesan ...

TITLE: PROCESS FOR PREPARATION OF 1-PHENYLOCTANE ABSTRACT The present invention provides an improved process for the preparation of 1-Phenyloctane of formula (I); intermediate used in preparation of pharmaceutical ingredient such as Fingolimod.

PHARMACEUTICAL COMPOSITION OF CABOZANTINIB AND PROCESS OF PREPARATION THEREOF ABSTRACT: The present subject matter relates to a solid oral pharmaceutical composition comprising Cabozantinib or a pharmaceutically acceptable salt thereof and at least one pharmaceutical acceptable excipient. The present subject mat...

PHARMACEUTICAL COMPOSITION CONTAINING COMBINATION OF MELOXICAM AND RIZATRIPTAN AND PROCESS OF PREPARATION THEREOF ABSTRACT: The present subject matter relates to a solid oral pharmaceutical composition comprising combination of meloxicam and rizatriptan or a pharmaceutically acceptable salt thereof and at least ...

The present subject matter provides amorphous solid dispersions of venetoclax or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising said amorphous solid dispersions. The present subject matter also provides methods for the preparation of said solid dispersions and compositions. Th...

The present invention relates to process for the preparation of (R)-2-(2, 5-difluorophenyl) pyrrolidine, a key intermediate used for the preparation of API in pharmaceutical filed. Dated this 08 th December 2021 Dr. S.Ganesan

PHARMACEUTICAL COMPOSITION OF DAROLUTAMIDE The present subject matter relates to a solid oral pharmaceutical composition comprising, darolutamide or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. The process to prepare such a pharmaceutical composition is also...

ABSTRACT TITLE: “AN IMPROVED PROCESS FOR PREPARATION OF PONATINIB HYDROCHLORIDE” The present application provides an improved process for preparation of Ponatinib hydrochloride. Dated this: 01st of August 2...

The present subject matter relates to a solid oral pharmaceutical composition comprising combination of azilsartan and chlorthalidone or a pharmaceutically acceptable salt thereof with at least one pharmaceutically acceptable excipient. The present subject matter also relates to a fixed dose pharmaceutical compositi...

Present disclosure is directed to solid pharmaceutical compositions of ivosidenib or pharmaceutically acceptable salt thereof and process for preparation of such compositions.

The present invention relates to a packaging system for pharmaceutical products comprising an absorbent. Furthermore, invention is also related to a process for purification of pharmaceutical products, wherein process optionally comprises treating with an antioxidant.

TITLE: “AN IMPROVED PROCESS FOR THE PREPARATION OF IRON CARBOHYDRATE COMPLEX COMPOUNDS” ABSTRACT The present application relates to an improved process for the preparation of iron carbohydrate complex. The present application more particularly relates to an improved process for the preparation of iron sucrose co...

The present invention relates to a multi-orifice oscillatory baffled reactor in which perforated baffle plates are surrounded by two layers of internal spiral coils to enhance turbulence and thereby overall mass and heat transfer for conducting chemically fast and exothermic reactions.

PHARMACEUTICAL COMPOSITION OF TRAMETINIB AND PROCESS OF PREPARATION THEREOF ABSTRACT: The present subject matter relates to a pharmaceutical composition comprising Trametinib or a pharmaceutically acceptable salt thereof and at least one pharmaceutical acceptable excipient. The present subject matter also relate...

STABLE PHARMACEUTICAL COMPOSITIONS FOR INHIBITING FORMATION OF NITROSAMINES ABSTRACT: The present subject matter relates to a stable pharmaceutical composition comprising an active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof and at least one pharmaceutical acceptable excipient. The su...

PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF LEVODOPA AND CARBIDOPA The present subject matter relates to a solid oral pharmaceutical composition comprising combination of levodopa and carbidopa as an active ingredient and dosage form comprises two types of components, the first components comprises imm...

Title – An improved process of preparation of Octreotide or its salt thereof. The present invention relates to an improved preparation process of Octreotide or its salt thereof of Formual-1. Formula-1

ABSTRACT TITLE: “AN IMPROVED PROCESS OF PREPARATION OF TIRZEPATIDE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF” The present invention relates to an efficient process for the preparation of Tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention also relates to novel fragments as inte...

ABSTRACT TITLE: “POLYMORPH OF RIBOCICLIB SALT” The invention relates to polymorph of Ribociclib citrate salt and pharmaceutical compositions thereof. The present invention also relates to preparation method thereof. In particular, the invention relates to Ribociclib citrate dihydrate. ...

ABSTRACT “TITLE: AN IMPROVED PROCESS OF PREPARATION OF GLUCAGON, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF” The present invention relates to an efficient process of Glucagon or a pharmaceutically acceptable salt thereof. The present invention also relates to a novel fragment as intermediates and use thereof ...

Title – An improved process of preparation of Semaglutide The present invention relates to an efficient process for the preparation of Semaglutide or a pharmaceutically acceptable salt thereof. The present invention also relates to novel fragments as intermediates and use thereof in the preparation of Semaglutide. ...

ABSTRACT: Stable injectable compositions of epinephrine The present subject matter relates to stable injectable compositions comprising epinephrine or a pharmaceutically acceptable salt thereof, a tonicity agent, an antioxidant, a buffering agent, a pH adjusting agent and optionally other pharmaceutically ...

STABLE PHARMACEUTICAL COMPOSITION COMPRISING VASOPRESSIN The present subject matter relates to a stable pharmaceutical composition, comprising vasopressin or pharmaceutically acceptable salts thereof as an active ingredient and suitable buffer, wherein the composition is for intravenous use. Further the stable ...

Title of the invention: An Improved Photochemical process for the preparation of a 4’-bromomethyl-2-cyanobiphenyl. The present invention relates generally to the preparation of bromo methyl biphenyl derivatives. More specifically, the present invention relates to an improved process for the preparation of a 4’-...

ABSTRACT PHARMACEUTICAL COMPOSITION COMPRISING BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION AND PROCESS OF PREPARING THEREOF 5 The present invention relates to an injectable pharmaceutical composition comprising bupivacaine or a pharmaceutically acceptable salt thereof. In particular, the present invention further ...

STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING TIRZEPATIDE Abstract- The present subject matter relates to a stable pharmaceutical compositions comprising an incretin analog with activity at glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide- 1 (GLP-1) receptor. The present subj...

A STABLE PHARMACEUTICAL COMPOSITION OF VILOXAZINE AND PROCESS OF PREPARATION THEREOF The present subject matter relates to a stable pharmaceutical composition comprising a therapeutically effective amount of Viloxazine or a pharmaceutically acceptable salt thereof, as an active ingredient, and at least one phar...

ABSTRACT TITLE: “AN IMPROVED PROCESS FOR REDUCING CONTENT OF NITROSAMINE IMPURITY IN DRUG SUBSTANCE.” The present invention relates to process for reducing content of nitrosamine impurity represented by formula (II) in drug substance of formula (I) or its intermediate of formula (I) or its salt thereof, which comp...

Title – Process for preparation of Momelotinib or its acid addition salts. The present invention relates to a process for preparing Momelotinib of Formula (I) or its acid addition salts. Dated this 23rd of Apr. 2025 ...

ABSTRACT TITLE: NOVEL CATALYSTS AND THEIR USE IN PREPARATION OF OPTICALLY ENRICHED ISOXAZOLINE COMPOUNDS The present invention relates to novel catalysts and their use in preparation of optically enriched isoxazoline compounds. The present invention relates to novel quinine, quinidine, cinchonine or cinchonidine b...

ABSTRACT PHARMACEUTICAL COMPOSITION OF LAROTRECTINIB OR SALTS THEREOF The present invention relates to a pharmaceutical composition comprising Larotrectinib or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, and a method for preparing said composition. ...

ABSTRACT TITLE: “SOLID FORMS OF RITLECITINIB OR ITS SALTS” The present invention relates to a solid form of acid addition salt of Ritlecitinib, wherein the acid addition salt is selected from group consisting oxalate, fumarate, hydrochloride, sulphate, acetate, formate, methanesulfonate and succinate. More par...

ABSTRACT TITLE: “AN IMPROVED PROCESS FOR PREPARATION OF PREPARATION OF TRAMETINIB” The present application provides an improved process for preparation of preparation of Trametinib”. ...